Rare Daily Staff
BioNTech and Genevant Sciences said that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases.
The collaboration will combine Genevant’s lipid nanoparticle delivery technology with BioNTech’s mRNA drug discovery platform to develop therapeutics.
Under the terms of the agreement, Genevant and BioNTech will pursue the co-development and co-commercialization of the five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs equally. The companies expect to initiate clinical development in 2020.
The companies have also agreed to a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs. Genevant is eligible to receive significant commercial milestones for the oncology licenses.
“This 50-50 partnership to develop rare disease mRNA therapeutics recognizes the critical importance of both best-in-class nucleic acids and their delivery in RNA drug development,” said Paris Panayiotopoulos, executive chairman of Genevant. “BioNTech’s impressive molecular design expertise and Genevant’s leadership in RNA delivery are the ideal combination for developing cutting edge mRNA therapies for rare disease patients who have limited or no treatment options today.”
July 10, 2018
Photo: Paris Panayiotopoulos, executive chairman of Genevant